Moxi vs BBL (and Why Many Med Spas Combine Them)

Both treatments are made by Sciton and run on the same device platforms, but they use different kinds of light.

Moxi is a fractionated, non-ablative 1927 nm laser — in ASDS's definitions, a non-ablative laser creates heat without injuring the skin surface, while ablative resurfacing removes layers of skin.

Sciton says a Moxi treatment takes 8–10 minutes, penetrates about 100–200 microns into the skin, and recommends 2 to 4 treatments.

BBL — short for BroadBand Light — is not a laser.

It is Sciton's own brand of intense pulsed light (IPL), a category ASPS defines as a minimally invasive, non-laser light treatment that emits multiple wavelengths, which the skin absorbs and converts to heat, targeting pigment, blood vessels and hair follicles.

Sciton developed its BroadBand Light technology from 2004, launched BBL HERO in 2020, and released the current BBL HEROic in 2024, adding motion tracking, automated pulse placement and nine swappable wavelength filters.

That is the mechanical difference in one line: a single laser wavelength working at a shallow depth, versus broad-spectrum light flashes filtered to different bands.

Everything else on this page — what each targets, downtime, price — follows from it.

Each treatment also has its own guide on this site: the Moxi laser hub and the BBL photofacial hub.

BBL is the color device.

Sciton's Forever Young BBL protocol is aimed at aging and sun damage — age spots, freckles, redness and small vessels — and Sciton says BBL HEROic's light modes treat skin types I–V for pigment, vascular and rosacea redness, mild-to-moderate inflammatory acne and hair removal.

Moxi's lane is set by its clearance, with a naming caveat.

The 510(k) covering Sciton's 1927 nm wavelength (K182173, cleared 6 March 2019) lists coagulation of soft tissue, actinic keratosis, and benign pigmented lesions such as lentigos (age spots), solar lentigos (sun spots) and freckles — melasma is not listed.

The document names the platform's 1927 nm laser rather than the Moxi trade name, and our research did not locate a Moxi-specific 510(k) summary, so we describe the clearance at the wavelength level.

Pigment therefore sits in both devices' territory: age spots, sun spots and freckles are cleared uses of the 1927 nm wavelength, and sun damage and its spots are what Sciton's Forever Young BBL protocol targets.

Texture is where the paths split.

The 1927 nm clearance names no wrinkle or texture indication — “prejuvenation” and “glow” are Sciton marketing terms, not cleared indications — and BBL is, per ASPS's definition, a light device for pigment and vessels rather than a resurfacing laser.

Sciton positions Moxi for uneven tone and texture, and a 2020 review of 1440/1927 nm non-ablative fractional lasers — a different device, not Moxi — reports improvements in tone, texture, fine lines and discoloration with transient side effects and minimal downtime.

Every figure in the table is Sciton's own published description of its devices, and our research found no independent trial comparing the two devices head to head.

Sciton itself markets the pairing: “MOXI combined with BBL HEROic,” delivered from the same mJOULE platform, which hosts both handpieces.

The pitch follows from the division of labor above — one device for color, one for tone and texture — though that framing is the manufacturer's, and our research found no independent comparative data behind it.

The BBL half may carry Sciton's “Forever Young BBL” branding, its protocol name for a BBL HEROic treatment aimed at aging and sun damage.

Sciton says sessions take about 30 minutes and that patients feel warm for 30–60 minutes afterward.

The study behind the “Forever Young” concept deserves a close read: a small Stanford pilot published in the Journal of Investigative Dermatology in 2013 found that BBL treatment shifted the expression of 1,293 of 2,265 aging-associated RNAs toward a youthful pattern.

It measured gene expression, not visible clinical results.

On downtime, Sciton's own published numbers put both devices at the light end of its range: Moxi is described as little-to-no downtime, and Forever Young BBL's downtime is “typically minimal.” For contrast, Sciton's Halo — its hybrid fractional laser, which adds an ablative wavelength Moxi does not have — lists 3 to 5 days of downtime on its own patient page.

That is one maker's published range, not an independent measurement.

What no source specifies is the combination.

We found no manufacturer or clinical source giving the combined downtime of a Moxi plus BBL session, or which device should be done first.

We also found no independent, Moxi-specific day-by-day recovery timeline, so any hour-by-hour description you see online rests on clinic or manufacturer descriptions.

On price, there is no national anchor to quote.

ASPS's 2025 statistics release does not report minimally invasive procedure fees at all, so no current ASPS average fee exists for IPL/BBL, and we could not confirm a national price for Moxi either.

The number of sessions is a main price driver, and Moxi is a 2 to 4 treatment series by Sciton's own recommendation, so a “Moxi plan” can be several visits.

With no national figure found for either device, what a practice charges — per session or in packages, and what a package includes — is set locally: ask whether a quoted package includes both devices, how many passes of each, and over how many visits.

Start from the complaint you want addressed, not from the device name.

If color leads — age spots, freckles, general redness — BBL is the device Sciton builds for that job.

If uneven tone and texture lead, Moxi is Sciton's fractional 1927 nm option, and the 1927 nm clearance covers age spots, sun spots and freckles too.

Which one fits a given face is a question for the licensed provider who examines your skin, because the two overlap on pigment.

Skin type is a real filter on the BBL side: Sciton says BBL HEROic's light modes treat skin types I–V on the Fitzpatrick scale, not VI, and describes only its SkinTyte infrared mode as usable on types V and VI.

Sciton's claim that Moxi suits all skin types, year-round, rests on the 1927 nm wavelength targeting water rather than pigment — it is the maker's claim, not an independent finding.

If you book a combined session, ask two things up front: who will operate each handpiece, and in what order.

Sciton promotes Moxi as “easily delegable” — designed to be performed by staff — but who may legally operate it is set by state law, so it is a fair question even at a physician-led practice.

On order, there is no published answer: our research found no source specifying whether BBL or Moxi should come first.